International Journal of Phonosurgery & Laryngology

Register      Login

VOLUME 8 , ISSUE 2 ( July-December, 2018 ) > List of Articles

Original Article

Urinary Nitrosamines: An Underestimated Biomarker in Laryngeal Cancer

Ushirin Bose, Santosh K Misra

Keywords : Combined modality of tobacco consumption, Laryngeal cancer, 4(Methylnitrosoamino)-1-(3-pyridyl)-1butanone, 4-Methyl nitrosoamino-1-3-pyridyl-1 butanol, Urinary nitrosamines

Citation Information : Bose U, Misra SK. Urinary Nitrosamines: An Underestimated Biomarker in Laryngeal Cancer. Int J Phonosurg Laryngol 2018; 8 (2):61-64.

DOI: 10.5005/jp-journals-10023-1161

License: CC BY-NC 4.0

Published Online: 01-08-2019

Copyright Statement:  Copyright © 2018; The Author(s).


Laryngeal cancer is the ninth and the seventh most common cause of cancer in males in Asia and India, respectively, and enlisted as one of the tobacco-related cancers. The carcinogen in tobacco is the tobacco-specific nitrosamines (TSNAs). Both secondary and tertiary amines can react with nitrite yielding nitrosamines which are excreted in urine. This study aims at quantifying urinary nitrosamines. Aims and objectives: • To quantify urinary nitrosamines in smokers and subjects consuming chewable forms of tobacco. • Correlation of urinary nitrosamine levels with the development of laryngeal cancer. Materials and methods: This study was a retrospective cross-sectional study conducted in adult patients presenting at the outpatient department of ENT in a tertiary care hospital over a period of 2 years. One hundred twenty-six cases were studied in detail. The urine of all adult patients presenting with malignant or premalignant lesions of larynx was analyzed and the sample was then subjected to liquid chromatography followed by mass spectrometry and the final amount of urinary nitrosamines was obtained in picograms/nanoliter (pg/nL). Results: Out of 126 laryngeal lesions that presented at the outpatient department, 107 cases were malignant and 19 cases had premalignant lesions. The mean of quantity of urinary nitrosamines was found to be the highest 843pg/nL among the subjects practicing combined modality (smoke + smokeless) of tobacco consumption. The mean of urinary nitrosamines was significantly higher 778.23 pg/nL in smokers as compared with tobacco chewers 613.45 pg/nL. Out of the 107 patients of carcinoma larynx (Ca larynx), 78 cases were smokers suggesting smoking that has a stronger association in the development of carcinoma larynx. Conclusion: The amount of urinary nitrosamines was higher in smokers, high in cases when more than one modality of tobacco was consumed and was more in cases of malignancy of larynx as compared to benign lesions.

  1. Ferlay J, Soerjomataram I, et al. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide in 2012. Lyon, France: International Agency for Research on Cancer; 2012.
  2. Three-year Report of Population Based Cancer Registries 2009–2011. Bangalore: National Cancer Registry Program (ICMR). ICMR: Individual registry-wise annexure; 2013. pp. 92–150.
  3. IARC. Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. vol. 83, Lyon, France: International Agency for Research on Cancer; 2004. pp. 53–119.
  4. Bhonsle RB, Murti PR, et al. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Cancer 1969;24:832–849. DOI: 10.1002/1097-0142(196910)24:4<832::aid-cncr2820240427>;2-u.
  5. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988 Jun;9(6):875–884.
  6. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature Reviews Cancer 2003;3:733–744. DOI: 10.1038/nrc1190.
  7. WHO. Tobbacco or Health: A Global Status Report. Geneva: World Health Organization; 1997. pp. 10–48.
  8. Fasunla AJ, Ogundoyin OA, et al. Malignant tumors of the larynx: Clinicopathologic profile and implication for late disease presentation. Niger Med J 2016;57(5):280–285. DOI: 10.4103/0300-1652.190596.
  9. Spence T, Bruce J, et al. HPV Associated Head and Neck Cancer. Cancer 2016;8:75. DOI: 10.3390/cancers8080075.
  10. Danaei G, Vander Hoorn S, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784–1793. DOI: 10.1016/S0140-6736(05)67725-2; Jemal A, Siegel R, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96. DOI: 10.3322/CA.2007.0010.
  11. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194–1210. DOI: 10.1093/jnci/91.14.1194.
  12. Peto R, Darby S, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323–329. DOI: 10.1136/bmj.321.7257.323.
  13. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559–603. DOI: 10.1021/tx980005y.
  14. Dube MF, Green CR. Methods of collection of smoke for analytical purposes. Recent Adv Tobacco Sci 1982;8:42–102.
  15. Franklin WA, Haseltine WA. Postlabelling methods to detect and characterize infrequent base modifications in DNA. In: Friedberg EC, Hanawalt PC. ed. DNA Repair: A Laboratory Manual of Research Procedures. New York: Marcel Dekker, Inc; 1983. pp. 161–171.
  16. Gupta RC, Reddy MV, et al. 32P-postlabeling analysis of non-radioactive aromatic carcinogen–DNA adducts. Carcinogenesis (London) 1982;3(9):1081–92. DOI: 10.1093/carcin/3.9.1081.
  17. Carmella SG, Han S, et al. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol Biomarkers Prev 2003;12:1257–1261.
  18. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907–922. DOI: 10.1093/carcin/23.6.907.
  19. Ross RK, Yuan JM, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943–946. DOI: 10.1016/0140-6736(92)91528-G.
  20. Yuan JM, Ross RK, et al. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. JAMA 1996;275:1646–1650. DOI: 10.1001/jama.1996.03530450036029.
  21. Yuan JM, Stram DO, et al. Dietary cryptoxanthin and reduced risk of lung cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2003;12:890–898.
  22. Maier H, Tisch M. Epidemiology of Laryngeal Cancer: Results of the Heidelberg Case-Control Study. Acta Oto-Laryngologica 1997;117(527):160–164. DOI: 10.3109/00016489709124063.
  23. Fan Y, Yuan JM, et al. Alcohol, tobacco, and diet in relation to esophageal cancer: the shanghai cohort study. Nutr Cancer 2008;60:354–363. DOI: 10.1080/01635580701883011.
  24. Elwood JM, Pearson JC, et al. Alcohol, smoking, social and occupational factors in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Cancer 1984;34(5):603–612. DOI: 10.1002/ijc.2910340504.
  25. Carmella SG, Akerkar SA, et al. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomarkers Prev 1995;4:635–642.
  26. Hecht SS, Carmella SG, et al. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999;8:907–913.
  27. IARC. Smokeless tobacco and tobacco-specific nitrosamines. IARC Monogr Eval Carcinog Risks Hum. vol. 89, Lyon, France: International Agency for Reseach on Cancer; 2005.
  28. Wu W, Zhang L, et al. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U.S.-brand and non-U.S.-brand cigarettes from 14 countries. Nicotine Tobacco Res 2005;7:443–451. DOI: 10.1080/14622200500125898.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.